lumasiran
Selected indexed studies
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. (N Engl J Med, 2021) [PMID:33789010]
- Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. (Am J Kidney Dis, 2023) [PMID:35843439]
- Lumasiran: First Approval. (Drugs, 2021) [PMID:33405070]
_Worker-drafted node — pending editorial review._
Connections
lumasiran is a side effect of
Sources
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. (2021) pubmed
- Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. (2023) pubmed
- Lumasiran: First Approval. (2021) pubmed
- Lumasiran. (2006) pubmed
- Lumasiran. (2012) pubmed
- Lumasiran for primary hyperoxaluria type 1: What we have learned? (2022) pubmed
- Lumasiran: A Review in Primary Hyperoxaluria Type 1. (2024) pubmed
- PMID:40258103 (2023) pubmed
- PMID:37903203 (2023) pubmed
- Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside. (2022) pubmed